Clinical trials
Leukemia, Acute Lymphoblastic clinical trials
Below are recruiting leukemia, acute lymphoblastic clinical trials, each written for real people, not researchers. We’re tracking 398 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04888741RecruitingPhase 2
Trial testing reduced immune T cells before stem cell transplant
This Phase 2 trial looks at a transplant approach that reduces harmful immune cells (T cells) before or during an allogeneic stem cell transplant. It may help lower the risk of transplant complications while still letting the donor immune system fight the blood cancer.
Cardiff, WalesAges 16–70 - NCT05735717RecruitingPhase 2
T-cell transplant using depleted receptors for blood cancers
This Phase 2 study tests a specialized stem cell transplant that removes certain immune “T-cell” receptors to help treat blood cancers like acute leukemia. It may help your body rebuild a healthier immune system after high-dose treatment.
Minneapolis, MinnesotaAges Up to 60 years - NCT04972942RecruitingPhase 1
Immunotherapy for high-risk T-cell blood cancers after transplant
This Phase 1 study tests a targeted immune treatment given after strong pre-treatment (myeloablative chemo plus total-body radiation) before or along with an allogeneic stem cell transplant. It may help prevent the cancer from coming back in young people with high-risk T-cell ALL or certain T-cell lymphomas.
Phoeniz, ArizonaAges Up to 39 years - NCT05014165Recruiting
Cord blood study for leukemia with stored birth samples
This study looks at leukemia “genetic clues” using special stored samples, including cord blood saved at birth. It may help researchers better understand leukemia biology and how common mutations may show up early.
Minneapolis, MinnesotaAges Up to 25 years - NCT05029531RecruitingPhase 3
Immuno-chemotherapy for infants with B-lineage ALL
This trial tests a combination of medicines (immunotherapy plus chemotherapy) in babies diagnosed with a type of leukemia called B-lineage acute lymphoblastic leukemia (ALL). It aims to improve how well treatment works and is delivered safely in very young children.
Moscow, Samory-Mashela,1Ages 1 day–12 months - NCT05031897RecruitingPhase 2
Haplo transplant with reduced donor mismatch and radiation
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
Philadephia, PennsylvaniaAges 18 years+ - NCT05038696RecruitingPhase 1
CAR T-cell treatment for hard-to-control B-ALL
This Phase 1 trial tests a personalized “CAR T” cell treatment for people with relapsed or treatment-resistant B-lymphoblastic leukemia (B-ALL). It may help the immune system find and kill leukemia cells, especially when leukemia has not responded to standard treatment.
SingaporeAges 6 months–80 years - NCT05043571RecruitingPhase 1
CAR T-cell therapy for relapsed T-cell leukemia
This early-phase trial tests a lab-made immune cell treatment (CAR T-cells) aimed at T-cell leukemia that has come back or did not respond. It may help by targeting leukemia cells with a specific marker (CD7), especially in patients who failed standard treatment.
SingaporeAges 6 months–65 years - NCT05054257RecruitingPhase 1
CAR T19 for hard-to-treat blood cancers that have CD19
This Phase 1 study tests CAR T cells designed to attack cancer cells that carry a marker called CD19. It’s for adults with certain relapsed or treatment-resistant B-cell leukemias (ALL) or lymphomas (NHL) where other treatments may not have worked.
PragueAges 18–80 - NCT05210907RecruitingPhase 1
Hospital-made CD19 CAR-T for relapsed leukemia in children
This Phase 1 study tests a homemade (hospital-manufactured) immune treatment called CD19 CAR-T for children and teens with a type of leukemia that has come back or did not respond. It may help by targeting leukemia cells that carry the CD19 marker.
SeoulAges birth–25 years - NCT05281809RecruitingPhase 2
CAR T-cell therapy made locally for B-cell blood cancers
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
Pittsburgh, PennsylvaniaAges 18–79 - NCT05292664RecruitingPhase 1
Venetoclax trial for high-risk blood cancers in young patients
This Phase 1 study tests venetoclax to treat certain high-risk blood cancers in children, teens, or young adults. It is designed to see if the drug can work safely for patients whose disease has returned or did not respond to prior treatment.
San Francisco, CaliforniaAges 1–40 - NCT05310591RecruitingPhase 1/Phase 2
Study anti-PD1 treatment with Kymriah re-dosing for leukemia
This Phase 1/2 trial studies giving an anti-PD1 antibody (like pembrolizumab or nivolumab) along with a second Kymriah (tisagenlecleucel) infusion in children and young adults whose B-cell leukemia is coming back or their Kymriah effect has faded. It may help the new immune treatment work better after the first Kymriah.
BordeauxAges 1–25 - NCT05326919Recruiting
Study biobank for people newly diagnosed with certain blood cancers
This study follows people who are newly diagnosed (and haven’t been fully treated yet) with specific leukemia or related blood disorders to help researchers learn which treatments may work best. It may help by connecting you to a larger “precision medicine” patient group for future research.
BobignyAges Any age - NCT05333302RecruitingPhase 1
CAR-T treatment study for children and young adults with CD19 leukemia
This Phase 1 study tests a CAR-T cell treatment made to target CD19 in children and young adults whose leukemia or lymphoma has come back or did not respond to prior treatment. It aims to see how the treatment works and how safe it is in this age group.
Minsk, Minsk OblastAges 1–30 - NCT05334823RecruitingPhase 2
CAR T-cell treatment for CD19-positive relapsed leukemia in children
This Phase 2 trial tests pCAR-19B, a customized immune-cell treatment for children and teens with CD19-positive B-ALL that has come back or did not respond to standard therapy. If eligible, you would receive the cell infusion after cell collection and testing to make sure the leukemia cells have the right marker.
Beijing, Beijing MunicipalityAges 3–21 - NCT05418088RecruitingPhase 1
CAR T-cell therapy for hard-to-treat B-cell cancers
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
Columbus, OhioAges 2 years+ - NCT05442515RecruitingPhase 1/Phase 2
CAR T-cell treatment for hard-to-treat B-cell cancers in youth
This trial tests a personalized immune-cell therapy (CAR T cells) made to attack B-cell cancers that have come back or did not respond to prior treatment. It aims to see how well the treatment works and how safe it is in children and young adults.
Bethesda, MarylandAges 3–39 - NCT05501899RecruitingEarly Phase 1
Levocarnitine to protect the liver during ALL chemotherapy
This early-phase study tests whether levocarnitine can reduce liver injury from a chemotherapy medicine called asparaginase in people with high-risk acute lymphoblastic leukemia (ALL). If you’re eligible, you would take levocarnitine by mouth alongside your planned standard cancer treatment to see if the liver stays healthier.
Orange, CaliforniaAges 5–29 - NCT05519579RecruitingPhase 2
Spinal chemotherapy to help protect the brain during blinatumomab
This trial studies giving medicine into the spinal fluid (intrathecal chemotherapy) to lower the risk of brain/nerve side effects from blinatumomab. It’s for adults with certain types of B-cell acute lymphoblastic leukemia (ALL) who are starting their first cycle.
Atlanta, GeorgiaAges 18 years+ - NCT05535855RecruitingPhase 1
UCD19 CAR T for adult ALL with MRD in remission
This early-phase study tests a personalized immune-cell treatment (CAR T) for adults with B-cell acute lymphoblastic leukemia (ALL) who still have tiny amounts of cancer detectable by a special test called MRD. It aims to improve outcomes for people who are in first remission but not completely “cancer-free” by MRD testing.
Aurora, ColoradoAges 18 years+ - NCT05579132RecruitingPhase 1/Phase 2
Study drug for relapsed or hard-to-treat B-cell leukemia
This early study tests MK-1045 in people with precursor B-cell acute lymphoblastic leukemia (B-ALL) that has come back or did not respond to earlier treatment. It may help shrink leukemia and improve remission in patients with limited options.
Chongqing, Chongqing MunicipalityAges 2 years+ - NCT05581030RecruitingPhase 1
Newly diagnosed ALL: testing a treatment after Hyper-CVAD
This Phase 1 study looks at a treatment approach for people newly diagnosed with Philadelphia-negative B- or T-cell acute lymphoblastic leukemia (ALL) after completing a specific chemotherapy course called Hyper-CVAD 1A. It aims to see if the treatment can be given safely and how well it may work for this type of leukemia.
Tampa, FloridaAges 18–50 - NCT05648019RecruitingPhase 2
CD19 CAR T-cell therapy for tough B-cell blood cancers
This Phase 2 study tests a one-time CAR T-cell treatment aimed at CD19, a target found on many B-cell leukemias and lymphomas. It’s for people whose disease has come back or hasn’t responded to prior treatments, or who can’t have a stem cell transplant.
SingaporeAges birth–70 years
Hear when a new Leukemia, Acute Lymphoblastic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia, acute lymphoblastic?
- Yes. Clin2 currently lists 398 recruiting leukemia, acute lymphoblastic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia, acute lymphoblastic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia, acute lymphoblastic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.